This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Achillion Pharmaceuticals, Inc.
Drug Names(s): ACH-702
Description: ACH-702 has a target profile against bacterial DNA replication enzymes and potent, broad-spectrum activity. ACH-702 acts against multi-drugresistant bacteria in a laboratory evaluation of recent clinical isolates obtained from infected patients, as well as in preclinical models of infection. The spectrum of activity includes inhibition of the DNA replication enzymes: gyrase, topoisomerase IV and primase. The drug has demonstrated bactericidal killing activity against multi-drugresistant methicillin-resistant Staphylococcus aureus, or MRSA. A number of the other drugs currently used to treat MRSA infections are bacteriostatic, meaning they are able to prevent the growth of new bacteria, but have a limited effect on the bacteria existing at the time of treatment.
Additional information available to subscribers only: